In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Hims & Hers Health ($HIMS) is one of the market’s most hotly debated stocks. The telehealth platform is shaking up ...